NF-κB mediates resistance towards diverse cancer therapeutics by inhibition of apoptosis, and inhibition of NF-κB sensitizes cancer cells towards anticancer drugs (e.g., doxorubicin, imatinib), cytotoxic phytochemicals (e.g., curcumin), biological agents (e.g., β-IFN, TRAIL), and radiation [47,54,55,56,57,58,59]. This evidence concerns the gene NFKB1 and cancer.